3 ASX Penny Stocks With Market Caps Under A$400M

Australian shares are currently in a state of uncertainty, with the ASX 200 futures showing minimal movement amid global economic fluctuations and rising oil prices. In such a landscape, identifying stocks with strong fundamentals becomes crucial for investors seeking opportunities. Penny stocks, though an older term, still represent smaller or newer companies that can offer significant growth potential when backed by solid financials.

Underneath we present a selection of stocks filtered out by our screen.

Bailador Technology Investments (ASX:BTI)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Bailador Technology Investments Limited is a venture capital firm that focuses on series A, mid venture, growth capital, late venture, and expansion investments in companies beyond the start-up phase, with a market cap of A$154.22 million.

Operations: The company generates revenue from its Internet Related Businesses segment, amounting to A$48.51 million.

Market Cap: A$154.22M

Bailador Technology Investments, with a market cap of A$154.22 million, has seen significant earnings growth of 54.6% over the past year despite a 6% annual decline over five years. The company is debt-free and trades at a 22.8% discount to its estimated fair value, suggesting potential upside for investors. However, its dividend yield of 7.16% is not covered by free cash flows and its return on equity stands at a low 9.5%. Bailador's seasoned board and management team provide stability as it navigates the venture capital landscape with substantial short-term assets covering liabilities effectively.

• Jump into the full analysis health report here for a deeper understanding of Bailador Technology Investments.
• Understand Bailador Technology Investments' track record by examining our performance history report.

Spheria Emerging Companies (ASX:SEC)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Spheria Emerging Companies Limited is an investment company based in Australia with a market capitalization of A$155.24 million.

Operations: The company generates revenue from investment activities amounting to A$26.30 million.

Market Cap: A$155.24M

Spheria Emerging Companies, with a market cap of A$155.24 million, boasts strong financial health, having no debt and substantial short-term assets (A$157.6M) covering both short-term and long-term liabilities. Its earnings grew significantly by 86.9% over the past year, surpassing industry growth rates despite a historical decline over five years. The company offers a dividend yield of 6.02%, although it's not well supported by free cash flows due to its high payout ratio. Recent changes include transitioning from quarterly to monthly dividends, fully franked at the corporate tax rate of 30%, reflecting an ongoing commitment to shareholder returns amidst stable volatility levels.

• Unlock comprehensive insights into our analysis of Spheria Emerging Companies stock in this financial health report.
• Review our historical performance report to gain insights into Spheria Emerging Companies' track record.

Starpharma Holdings (ASX:SPL)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Starpharma Holdings Limited is a biopharmaceutical company focused on the research, development, and commercialization of dendrimer technology for pharmaceutical and healthcare applications globally, with a market cap of A$317.97 million.

Operations: The company generates revenue of A$14.58 million from the discovery, development, and commercialization of dendrimers.

Market Cap: A$317.97M

Starpharma Holdings, with a market cap of A$317.97 million, is focused on dendrimer technology but remains unprofitable despite reducing losses by 21.1% annually over five years. The company has a robust cash runway exceeding three years and minimal debt relative to its cash reserves, indicating financial stability. Recent discussions highlighted progress in their radiopharmaceutical platform, potentially enhancing future prospects. While trading significantly below estimated fair value, Starpharma's earnings are expected to grow substantially at 91.8% per year according to forecasts, though current profitability challenges persist amidst improved volatility and stable shareholder equity positions.

• Click to explore a detailed breakdown of our findings in Starpharma Holdings' financial health report.
• Review our growth performance report to gain insights into Starpharma Holdings' future.

Key Takeaways

• Click this link to deep-dive into the 407 companies within our ASX Penny Stocks screener.
• Curious About Other Options? We've found 9 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com